Phase I/II Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)

Trial Profile

Phase I/II Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Pembrolizumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 21 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top